Testing labs in Lenexa

RD2Rx, LLC is a pharmaceutical contract services organization founded in 2012 and headquartered in Lenexa, Kansas, USA. The company provides comprehensive services to pharmaceutical firms navigating the journey from research and development through regulatory approval and prescription market entry. Originally founded as an arm of Ailex Pharmaceuticals Pvt. Ltd., RD2Rx has grown into a full-service partner for small to medium-sized pharmaceutical companies seeking cost-effective product development, cGMP analytical testing, regulatory strategy, and compliance support under one roof. The company name reflects its core mission: bridging the gap from R&D (research and development) to Rx (the prescription marketplace). The company's in-house cGMP analytical laboratory is central to its service offering, providing pharmaceutical testing capabilities designed to accelerate client development timelines. The lab supports analytical method development and validation, in-process testing, and release testing across a range of pharmaceutical dosage forms. In January 2017, RD2Rx moved into a state-of-the-art 20,000 square foot facility on a three-acre campus in Lenexa, Kansas, equipped with on-site UPS power backup and emergency generator, fully temperature-controlled laboratory environments, and infrastructure capacity to expand by an additional 40,000 square feet. The facility is FDA registered and inspected, cGMP compliant, and holds a DEA license covering controlled substance schedules II through V, enabling work with a broad range of pharmaceutical products including scheduled compounds. RD2Rx specializes in pharmaceutical product development with deep expertise in first-to-market and niche generic drug products, as well as improvements to existing products pursued via the FDA 505(b)(2) regulatory pathway. The 505(b)(2) pathway allows sponsors to rely in part on existing published safety and efficacy data, making it a strategically efficient route for new formulations, new routes of administration, line extensions, and new indications. RD2Rx has successfully developed and commercialized multiple pharmaceutical products through this and other pathways, spanning a range of dosage forms, demonstrating broad formulation and analytical development experience across drug classes and delivery systems. Regulatory affairs support is a cornerstone of the RD2Rx value proposition. The firm has positioned itself as a pioneer in electronic regulatory submissions, with deep expertise spanning the full spectrum of FDA submission types: eCTD (electronic Common Technical Document), SPL (Structured Product Labeling), IND (Investigational New Drug), NDA (New Drug Application), ANDA (Abbreviated New Drug Application), DMF (Drug Master File), NADA, and ANADA applications. The team also assists clients with drug product listing, establishment registration, and navigating complex FDA compliance matters such as field alert reports and warning letter responses, providing comprehensive regulatory coverage from early development through commercial launch. Compliance support at RD2Rx draws on extensive experience with FDA current Good Manufacturing Practice (cGMP) regulations applicable to pharmaceutical manufacturers and testing laboratories. The company provides cGMP auditing services, quality system consulting, and remediation support for firms facing inspectional findings or seeking to elevate their quality infrastructure. A particularly notable credential is the facility's track record of multiple FDA inspections with zero Form 483 observations—an achievement that reflects the strength of the company's internal quality management systems and standard operating procedures, and gives client companies confidence in the regulatory defensibility of data generated at the site. Pharmacоvigilance support rounds out the company's service portfolio. RD2Rx offers comprehensive post-market safety monitoring services tailored specifically to small and medium-sized pharmaceutical companies that lack dedicated in-house pharmacovigilance infrastructure. These services encompass adverse event monitoring, signal detection, and regulatory safety reporting aligned with FDA post-marketing requirements, allowing emerging pharmaceutical sponsors to fulfill their ongoing obligations without building large internal safety departments. RD2Rx operates with a global delivery model: its primary GMP analytical laboratory and product development operations are based in Lenexa, Kansas, while support operations in New Delhi, India provide continuous round-the-clock coverage. This dual-geography structure enables sustained productivity across time zones and is particularly valuable during intensive regulatory submission campaigns or compressed development timelines. The company primarily serves small and mid-sized pharmaceutical companies, generic drug manufacturers, and specialty pharmaceutical firms seeking experienced contract research and services organization (CRO/CSO) partnerships to efficiently bring differentiated drug products to the US prescription market.